HAC(SH:600202) Shang Hai Zheng Quan Bao·2025-11-21 19:58Group 1 - The company held its ninth temporary board meeting on November 21, 2025, where all nine directors participated and approved the proposal to transfer 40% equity of its subsidiary, Harbin Fushanchuan Biotechnology Development Co., Ltd. [2][4][9] - The board's decision to transfer the equity was based on a strategic review and aims to optimize resource allocation and improve operational efficiency [6][24]. - The market value of the 40% equity stake is assessed at RMB 381.26 million, with the final price subject to approval by the state-owned assets regulatory authority [6][13][23]. Group 2 - The subsidiary, Fushanchuan, reported a net loss of RMB 16.10 million in 2024, which is 218.83% of the company's previous year's net profit, leading to the decision to transfer the equity without requiring shareholder approval [7][9][24]. - The transfer process will be conducted through public listing on the Heilongjiang United Property Rights Exchange, with the final buyer and price to be determined through this process [8][10][24]. - The company will no longer hold any equity in Fushanchuan post-transfer, and the subsidiary will be excluded from the company's consolidated financial statements [6][24]. Group 3 - The company received a government subsidy of RMB 2 million on November 21, 2025, which is expected to positively impact future profits [28][29]. - The subsidy is classified as a government grant related to income and will be recognized in the current period's profit and loss [28].